Rowland & Co. Investment Counsel ADV Sells 1,664 Shares of Eli Lilly and Co (LLY)

Rowland & Co. Investment Counsel ADV trimmed its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 3.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 43,407 shares of the company’s stock after selling 1,664 shares during the period. Eli Lilly and makes up approximately 1.4% of Rowland & Co. Investment Counsel ADV’s holdings, making the stock its 23rd largest position. Rowland & Co. Investment Counsel ADV’s holdings in Eli Lilly and were worth $3,671,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. Acrospire Investment Management LLC raised its holdings in Eli Lilly and by 16.7% in the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after acquiring an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC purchased a new position in Eli Lilly and in the 2nd quarter worth approximately $128,000. San Francisco Sentry Investment Group CA purchased a new position in Eli Lilly and in the 2nd quarter worth approximately $129,000. Willingdon Wealth Management purchased a new position in Eli Lilly and in the 3rd quarter worth approximately $138,000. Finally, Wealthcare Advisory Partners LLC purchased a new position in Eli Lilly and in the 3rd quarter worth approximately $142,000. Hedge funds and other institutional investors own 76.31% of the company’s stock.

In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction on Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the sale, the senior vice president now directly owns 43,580 shares in the company, valued at approximately $3,646,338.60. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, SVP Jeffrey N. Simmons sold 12,500 shares of the business’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $86.46, for a total transaction of $1,080,750.00. Following the sale, the senior vice president now directly owns 124,522 shares of the company’s stock, valued at approximately $10,766,172.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 251,088 shares of company stock valued at $22,041,236. Company insiders own 0.20% of the company’s stock.

Shares of Eli Lilly and Co (NYSE LLY) traded up $0.29 on Thursday, reaching $86.39. 2,614,041 shares of the company’s stock were exchanged, compared to its average volume of 3,260,000. The stock has a market cap of $95,120.00, a price-to-earnings ratio of 41.14, a PEG ratio of 1.62 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38. Eli Lilly and Co has a 1-year low of $74.00 and a 1-year high of $89.09.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. The business had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period in the previous year, the business earned $0.88 EPS. research analysts expect that Eli Lilly and Co will post 4.22 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be paid a dividend of $0.5625 per share. The ex-dividend date is Wednesday, February 14th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 dividend on an annualized basis and a yield of 2.60%. Eli Lilly and’s payout ratio is currently 99.05%.

A number of equities analysts recently weighed in on LLY shares. Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 price objective for the company in a report on Thursday, October 26th. Piper Jaffray Companies restated a “buy” rating and issued a $105.00 price objective on shares of Eli Lilly and in a report on Friday, October 13th. Goldman Sachs Group restated a “buy” rating and issued a $95.00 price objective (up from $92.00) on shares of Eli Lilly and in a report on Thursday, October 5th. Cowen restated a “buy” rating and issued a $95.00 price objective on shares of Eli Lilly and in a report on Wednesday, October 4th. Finally, Berenberg Bank restated a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a report on Thursday, October 26th. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and ten have given a buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $92.14.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece on another publication, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The correct version of this piece can be viewed at https://stocknewstimes.com/2018/01/11/rowland-co-investment-counsel-adv-sells-1664-shares-of-eli-lilly-and-co-lly.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply